BMS-919373
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 09, 2022
Discovery and chemical development of BMS-919373 – a selective IKur inhibitor for the potential treatment of atrial fibrillation
(ACS-Fall 2022)
- "The transition to process chemistry, the initial scale-up route, commercial route exploration, and commercial route development led to an impactful C-H direct arylation. The development and mechanistic studies of the direct arylation led to a commercial route with significant improvements in yield, cost, and number of steps."
Atrial Fibrillation • Cardiovascular
November 06, 2018
Utilizing Native Directing Groups: Synthesis of a Selective IKur Inhibitor, BMS-919373, via a Regioselective C-H Arylation.
(PubMed, J Org Chem)
- "The strategy of leveraging this inherent directing group allowed the synthesis of this complex heterocycle in only six steps from commodity chemicals. The scope of the C-H activation was further investigated, and the generality of the transformation across a series of bicyclic aromatic heterocycles was explored."
Journal
May 24, 2019
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
(clinicaltrials.gov)
- P2; N=158; Terminated; Sponsor: Bristol-Myers Squibb; N=27 ➔ 158; Completed ➔ Terminated; Sponsor decision based on business reasons, unrelated to safety
Enrollment change • Trial termination
1 to 3
Of
3
Go to page
1